Dr. Rishal Rahman P: WARFARIN – Balancing Clot Prevention With Safe Monitoring
Dr. Rishal Rahman P, Clinical Pharmacist Intern at Aster MIMS Kottakkal, posted on LinkedIn:
”Day 14: WARFARIN – Balancing Clot Prevention with Safe Monitoring
Indications
Prevention and treatment of venous thromboembolism (VTE, DVT, PE)
Prevention of stroke/systemic embolism in atrial fibrillation
Prosthetic heart valve thromboprophylaxis
Secondary prevention after myocardial infarction
Mechanism of Action
Inhibits Vitamin K epoxide reductase complex (VKORC1) → prevents activation of clotting factors II, VII, IX, X and proteins C & S → ↓ coagulation.
Dosage
Initial: 2–5 mg/day orally
Maintenance: 2–10 mg/day (adjust per INR)
Target INR:
2.0–3.0 for most indications
2.5–3.5 for mechanical prosthetic valves
Clinical Pharmacist Tips
Monitor INR regularly (every 2–4 weeks once stable).
Maintain consistent dietary vitamin K intake (avoid sudden ↑/↓ in green leafy vegetables).
Strong drug–drug & food interactions → always check before prescribing.
Educate patients about bleeding signs (bruising, gum bleed, black stools).
Contraindications
Pregnancy (teratogenic)
Active bleeding, recent major surgery, hemorrhagic stroke
Severe uncontrolled hypertension
Poor compliance for monitoring
Drug Interactions
Increased effect (↑ bleeding risk): Antibiotics (e.g., metronidazole, TMP-SMX), amiodarone, antifungals, SSRIs
Decreased effect (↓ anticoagulation): Rifampin, carbamazepine, barbiturates, vitamin K-rich foods
NSAIDs, aspirin → ↑ bleeding risk (even without INR changes)
Adverse Drug Reactions (ADR)
Bleeding (most common, dose-dependent)
Skin necrosis (rare, usually within 3–10 days, esp. in protein C/S deficiency)
Purple toe syndrome
Teratogenicity (nasal hypoplasia, stippled epiphyses)”
Stay informed with Hemostasis Today.
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies
-
Jan 12, 2026, 01:55Frank Weinz on State-of-the-Art Thromboembolism Prophylaxis
-
Jan 12, 2026, 01:45Khurram Nasir on Where The Cholesterol Guidelines Are Headed
-
Jan 12, 2026, 01:35Nirav Dhanesha Shares The Lab’s Latest Publication on Neutrophil CD14 and DVT Link
-
Jan 12, 2026, 01:07Akshat Jain Presents The New Edition of Global Sickle Cell Disease Insight Publication
-
Jan 11, 2026, 21:05Simona Sacco Shares Expert Guidance for Clinicians on Minor Ischemic Stroke
-
Jan 11, 2026, 11:00Benjamin YQ Tan on Impacts of Early Cognitive and Psychological Statuses Post-Stroke
-
Jan 11, 2026, 10:46Salvador Payán Pernía: Leukodepletion Reduces Microplastic Burden in Red Blood Cell Concentrates